CSF3 and non-Hodgkin lymphoma: examined FN risk factors in patients with non-Hodgkin lymphoma who underwent a regimen comprised of rituximab and CHOP chemotherapy in a retrospective study, and found age, albumin, hemoglobin, and no prophylaxis with daily G-CSF during cycle 1 to be significant21.